• The company targets all current ketamine indications, including anesthesia and pain management.
• The U.S. is facing a severe ketamine shortage, prompting NRx to seek priority FDA review.
• NRX-100 eliminates benzethonium chloride, aligning with U.S. health initiatives to remove toxic preservatives.
• The company plans to petition the FDA to remove benzethonium chloride from all intravenous ketamine products.
• The filing complements the company’s NDA for NRX-100 for suicidal depression, with a PDUFA date expected in late 2025.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation of ketamine. The submission seeks approval for all existing ketamine indications, including its use in anesthesia and pain management (https://ibn.fm/hsgzo).

The move comes amid a significant shortage of ketamine in the United States, as noted by the American Society of Health-System Pharmacists. With demand rising and supply constrained, the company is requesting a priority review from the FDA.

NRX-100 is designed without benzethonium chloride, a compound recognized for its neurotoxic and cytotoxic properties. Its absence positions NRX-100 in line with broader public health efforts to eliminate harmful preservatives from medications. NRx plans to file a citizen’s petition urging the FDA to mandate preservative-free formulations for all ketamine intended for IV use.

The company aims to leverage the existing $750 million U.S. ketamine market and growing global demand, which is projected to reach $3.35 billion by 2034. According to a 2021 survey, an estimated 5.1 million Americans had received ketamine for medical uses in their lifetime, a number that continues to grow. With ketamine use expanding in both hospital settings and psychiatric care, NRx believes NRX-100 could gain traction among providers seeking safer alternatives.

Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals, commented on the ANDA submission’s timing in the context of a rapidly expanding market and an inadequate available supply. “We at NRx believe that safer, preservative-free formulations of ketamine will be increasingly preferred by physicians, patients, and regulators in this large and growing market,” Javitt said. “NRX-100 is designed to replace older formulations that rely on potentially neurotoxic and cytotoxic preservatives for stability and sterility. We have filed a U.S. patent on our novel, preservative-free formulation, which anticipates three years of room-temperature shelf stability.”

The move supplements NRx’s New Drug Application (“NDA”) currently underway for NRX-100 in the treatment of suicidal depression. That submission is expected to be reviewed by the FDA in late 2025 under the Prescription Drug User Fee Act (“PDUFA”).

Clinical data backing the NDA includes studies involving more than 1,000 patients and observational data from over 180,000 individuals. The company argues that NRX-100 has demonstrated non-inferiority to electroconvulsive therapy and superiority to both placebo and active placebo in reducing suicidality.

In April 2025, NRx secured a waiver of the $4.3 million NDA filing fee, citing the product’s public health relevance and the company’s small business status. The company was previously granted Fast Track designation for NRX-100 as part of a broader protocol in suicidal bipolar depression.

NRx is also pursuing patent protection for NRX-100, with claims extending through 2045. The formulation is designed to remain stable at room temperature for three years, which the company sees as another advantage over older ketamine products.

The company hopes that its preservative-free formulation can potentially set a new standard for ketamine delivery. In the context of increasing ketamine use for mental health and chronic pain, NRX-100 may become a safer alternative with fewer toxicity concerns. The combination of regulatory positioning, clinical backing, and public health alignment puts NRx in a unique position to compete in a sector undergoing both supply disruption and therapeutic evolution.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

• The company’s 3.79 MW Geddes facility is expected to begin generating revenue in June 2025.
• The initiative marks one of the first integrations of renewable energy and Bitcoin treasury management.
• Management will determine Bitcoin allocation based on market conditions and operational cash flow.
• The Geddes site, built on a closed landfill, reflects SolarBank’s dual focus on clean energy and land repurposing.
• This move could be extended to other solar and battery energy storage projects across the company’s 1+ GW pipeline.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is moving forward with its plan to integrate Bitcoin into its treasury operations by directing net revenue from its soon-to-be-operational Geddes Solar Power Project toward the digital asset. This step marks the company’s first allocation of cash flow to Bitcoin since revealing its treasury strategy earlier in June 2025 (https://ibn.fm/u9bqQ).

The Geddes Project, located in New York State, has a designed capacity of 3.79 megawatts of direct current electricity. Built on a repurposed landfill, the site reflects a broader trend in renewable energy of transforming brownfield sites into productive infrastructure. Once operational, expected before the end of June 2025, the project will sell electricity to local community solar subscribers through power subscription agreements.

After accounting for capital, operating costs, and debt service, net cash generated from the project will be allocated at management’s discretion to purchase Bitcoin. Timing and amounts will depend on market conditions, liquidity needs, and the price of Bitcoin.

SolarBank CEO Dr. Richard Lu described the move as “a sustainable way to add Bitcoin to SolarBank’s balance sheet.” He added that the initiative offers a hybrid approach: combining stable revenue from renewable energy generation with potential upside from holding Bitcoin.

“I am pleased we are moving forward with the first step in our Bitcoin treasury strategy. Geddes is the largest power producing assets that SolarBank will have operational and this strategy provides a sustainable way to add Bitcoin to SolarBank’s balance sheet,” Lu said. “By converting solar energy revenue into digital assets, we’re creating a unique value proposition that combines the stable cash flows of renewable energy with the potential appreciation of Bitcoin, while supporting grid decarbonization and distributed energy resources (‘DER’) expansion.”

The company’s broader strategy involves examining whether additional solar and battery energy storage projects could adopt the same model. As SolarBank continues to scale its operations across North America, this could lead to a more formalized approach to integrating Bitcoin across its clean energy portfolio.

SolarBank currently operates more than 32 MW of installed renewable energy capacity, with a 1+ gigawatt development pipeline in progress. The Geddes Project is the largest asset in its portfolio to date.

The mechanics of the strategy follow a four-step process: solar energy is generated, sold to subscribers, net cash flows to the company, and a portion is used to purchase Bitcoin. This creates two streams of value: predictable energy revenue and Bitcoin holdings.

Bitcoin allocations may be paused, modified, or discontinued based on various business conditions. As of June 4, no purchases have yet been made. Management intends to provide specific allocation percentages after the Geddes Project begins commercial operation.

SolarBank’s move adds a new dimension to ongoing debates around the intersection of digital finance and clean energy. The company is one of the first renewable energy firms to tie Bitcoin directly to revenue from energy production. By allocating surplus cash from clean energy, it aims to balance environmental considerations with financial innovation. With top tier project partnerships, including deals with CIM Group, Qcells, and Honeywell, SolarBank continues to build a portfolio that merges renewable infrastructure with flexible financial planning.

For more information, visit the company’s website at SolarBankCorp.com.

There are several risks associated with the development of the projects detailed in this report. The development of any project is subject to the continued availability of third-party financing arrangements for the project owners and the risks associated with the construction of a solar power project. There is no certainty the projects disclosed in this report will be completed on schedule or that they will operate in accordance with their design capacity.

This report contains forward looking information. Please refer to the press release entitled “Bitcoin Purchases to be made by SolarBank Using Net Cash from Geddes Solar Power Project” for additional details on the statements, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• The company offers a simple, AI-powered platform that helps providers identify their most valuable services, bringing clarity to complex insurance contracts, and highlighting where clinics can optimize revenue.
• The platform’s AI analytics help to identify high-risk patients and close care gaps efficiently, while letting providers track financial performance over time, aligning income with quality of care.
• Adageis continues to grow and expects to cover 580,000 patient lives by Q2 2025 and reach $100,000 in monthly recurring revenue.

As healthcare shifts further toward value-based care, one challenge continues to frustrate providers: understanding how care quality translates into financial outcomes. Adageis, a growing healthcare technology company with a patented AI-driven platform, is offering providers tools that both simplify operations and improve financial performance under value-based care models.

The platform, rebranded as a fintech AI solution, focuses on helping providers understand how their clinical decisions tie directly to revenue. According to Adageis, three central benefits stand out:

• Ease of use
• Visibility into insurance contracts
• Long-term financial tracking

One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards.

Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.

The software supports this by providing direct insight into performance metrics tied to value-based care models, allowing practices to focus on both patient outcomes and financial sustainability.

For many clinics, understanding how much they should be paid under different insurance agreements remains a challenge. Adageis aims to address that, by enabling its software to help providers determine how well they are being compensated for the care they deliver.

This is particularly important for high-performing clinics that may be underpaid for exceeding quality benchmarks. With Adageis, practices can identify which contracts are more favorable and structure their care delivery accordingly.

This functionality also assists newer practices that are transitioning away from fee-for-service models. The platform helps them assess which payer contracts are most lucrative under value-based frameworks, supporting growth without sacrificing quality.

In addition to point-in-time analysis, Adageis helps providers track how their focus on quality care is rewarded financially. By visualizing financial trends alongside patient care metrics, providers can make strategic decisions with better confidence. Clinics can see not just how they’re performing today, but how that performance evolves as care models change.

Beyond software, Adageis positions itself as an advocate for its clients. The company works directly with insurance payers on behalf of providers, helping them navigate negotiations and understand their entitlements. This hands-on approach is especially beneficial for small practices with limited administrative support.

The company also continues to work with investors to expand its offerings, aiming to develop tools tailored to the needs of small and mid-sized clinics.

Adageis’s patented ProActive Care Platform offers full integration with widely used Electronic Health Record (“EHR”) systems including AthenaHealth, Cerner, Epic, and others. This ensures that providers don’t need to overhaul their IT infrastructure to benefit from the system.

Additionally, its Risk Engine (“PRE”) identifies high-risk patients and care gaps, helping clinics deliver timely interventions and reduce avoidable costs. The platform supports proactive care, monitoring patient health beyond traditional office visits.

As of April 2025, Adageis covered over 260,000 patient lives. By the end of Q2, it expects to double that figure to 580,000 and reach $100,000 in monthly recurring revenue. The company also anticipates onboarding two to three new clients each month.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

As the world watches Foxconn and NVIDIA deploy smart robotics in Taiwan’s cutting-edge hospitals, the same technology driven future is quietly taking shape across the American hospitality industry. Led by companies like SkyTech Automated Solutions, a wholly owned subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF).

Foxconn’s recent unveiling of its NVIDIA-powered hospital robots signals a monumental shift: combining real-time AI with robotics to improve labor efficiency, safety, and service personalization. The smart hospital model represents not just a technological leap, but a redefinition of how service delivery is imagined in labor-intensive environments.

SkyTech is bringing that same revolution to the hospitality sector in the United States. Through service robots designed for hotels and restaurants, capable of autonomous delivery, sanitation, guest interaction, and operational logistics, SkyTech is tackling the industry’s labor cost crisis while enhancing guest experience and operational consistency.

Parallel Innovation: Hospitals and Hotels Share the Same DNA

Just as hospitals demand speed, precision, hygiene, and 24/7 service, so too do hotels. The Foxconn-NVIDIA collaboration focuses on surgical-grade robotics in patient-facing roles, like delivery of medicine and disinfection of rooms. Similarly, SkyTech’s hospitality robots automate tasks like:

• Housekeeping logistics — Enabling robotic deployment of linens and trash removal
• Food and beverage Concierge — Aiding the kitchen with hot and cold deliveries right to your door
• AI integrated dusting service — Eliminating the need for manual sweeping

By using edge computing and AI integration, SkyTech is also working toward adaptive intelligence, allowing robots to learn hotel-specific routines and guest preferences over time, increasing value the longer they’re deployed.

National Strategy and the Trump-Era Industrial Reset

The significance of this shift is amplified by macroeconomic and geopolitical context. Under the Trump administration, policies like the Tax Cuts and Jobs Act, tariffs targeting Chinese imports, and efforts to reshore critical manufacturing laid groundwork for a U.S. tech revival. Trump’s push to label robotics and AI as strategic national priorities accelerated capital inflows into sectors like automation, semiconductors, and logistics.

As a result, U.S. manufacturers and tech companies began prioritizing onshore innovation and automation. Robotics companies like SkyTech are direct beneficiaries of that policy environment, able to attract investor attention, partner with American industrial groups, and accelerate AI adoption in areas like hospitality that had long relied on low-wage manual labor.

Automation as a Solution, Not a Threat

While critics worry about job displacement, SkyTech’s deployment model shows the opposite. In hotels facing chronic staffing shortages post-COVID, robots aren’t replacing staff, they’re complementing them. Hotels using SkyTech robots have seen:

• Lower staff turnover, as repetitive labor is reduced
• Increased energy efficiency, through smart environmental control
• Improved hygiene and fewer guest complaints related to room service timing or amenities

Robots handle the boring and the burdensome, while human staff can focus on delivering the high-touch experiences that differentiate top-tier hotels.

The Road Ahead for Nightfood and SkyTech

As Nightfood Holdings builds a vertically integrated hospitality ecosystem, from late-night nutritional offerings to smart robotics, the alignment of SkyTech’s mission with global trends is clear. Like NVIDIA and Foxconn in the medical space, Nightfood and SkyTech are building a next-gen infrastructure for the American hotel sector, driven by automation, AI, and a new national focus on domestic technological leadership.

In the coming years, expect to see SkyTech robots in hundreds of mid-sized hotels and restaurant chains across the U.S., quietly and efficiently redefining what service means in the AI age.

For more information about the company, visit NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Third-Party Content Disclaimer

The IBN website may contain third-party content articles and other content submitted by third parties, including articles submitted through the IBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IBN providing you with this internet portal that makes accessible to you the ability to view third party content through the IBN site, IBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IBN expressly disclaims liability relating to such third-party content. IBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://IBN.fm/Disclaimer.

• Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline.
• The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL.
• Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations.
• Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways.
• With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support pipeline advancement and platform development.

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (“ADC”) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR(R) platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic(TM)) for non-small cell lung cancer (“NSCLC”) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (“TNBC”), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (“NHL”) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

• LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
• LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
• LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
• CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

MoneyShow, a company that has maintained market dominance in connecting self-directed investors and active traders with world-class financial experts, is proud to announce this year’s edition of its MoneyShow Masters Symposium Las Vegas. Scheduled for July 15-17, 2025, at Caesars Palace, the symposium will provide attendees with great opportunities to network, learn during in-depth sessions, and experience unrivaled access to industry experts.

This year’s event theme is “The Great Money Reset.” True to its theme, the event will feature a lineup of top experts who will provide all the guidance attendees need, showing them what to buy and what to sell. The program will cover all the competing economic, financial, political, and geopolitical forces shaping markets globally – to create a highly informative and interactive event that offers value to each attendee.

Some of the topics covered will include how to navigate today’s volatile market swings, why options trading volume is exploding, which new sectors will offer the greatest growth potential in 2025-2026, which alternative can help you diversify, and how to reduce portfolio swings and generate the most income. Top speakers will include Anas Alhajji, Managing Partner of Energy Outlook Advisors LLC; Carolyn Boroden, a Technical Analyst at ElliottWaveTrader.net; Mark Mahaney, Senior Managing Director and Head of Internet Research at Evercore ISI; Larry McDonald, Founder of The Bear Traps Report; and Carley Garner, Senior Commodity Market Strategist and Broker at DeCarley Trading.

MoneyShow has a legacy spanning more than four decades. It has a long history of creating successful investors and traders through timely education delivered by powerful experts, including best-selling authors, market analysts, portfolio managers, award-winning financial journalists, and newsletter editors. Under the leadership of Kim Githler, the Chair and CEO, and Aaron West, the President, the company has made a mark in the industry and remains the go-to brand for all things investment.

The brand has been lauded for providing great networking opportunities – and received praise for the quality of its speakers and panelists – with each attendee leaving with knowledge integral to building wealth. Each symposium has proven to be bigger than the previous one, and this year’s edition will be no exception. It will provide attendees an opportunity to gain a deeper understanding of the market and learn how to effectively allocate their portfolio in light of the evolving economic climate.

To learn more, please visit https://ibn.fm/EEtib

• Claude Zdanow began his entrepreneurial journey as a teenager, founding RockIT Studios in his parents’ basement
• Launched The Chainsmokers’ career and led Stadiumred Studios to associations to 30 Grammy nominations and 22 wins
• As CEO of Stadiumred Group, Claude Zdanow led multiple agency acquisitions, landed top clients like 7-Eleven, Brown-Forman, Disney’s FX Networks, and Steven Soderbergh’s Singani 63, and earned industry recognition including Adweek’s #3 Fastest Growing Agency and a spot on the Inc. 5000 list
• As CEO of ONAR Holdings, Zdanow is revolutionizing marketing for middle-market companies through AI-driven strategies and strategic acquisitions

Claude Zdanow’s entrepreneurial spirit ignited early. At just 15, he launched RockIT Studios in his parents’ basement, producing for major clients like Warner Brothers and Maybelline. This foundation in music production and brand collaboration laid the groundwork for Zdanow’s future successes across multiple industries.

In a recent interview on The TechMediaWire Podcast, Zdanow reflected on this journey and shared insights into the mission of his latest endeavor, ONAR Holdings (OTCQB: ONAR). “I have a bit of a non-traditional background,” he explained. “I started as a musician signed to a band on an imprint of Warner Bros. I parlayed that into starting a music company, then pivoted into advertising and marketing.”

Zdanow’s transition was marked by the founding of Stadiumred Studios in 2007, transforming Ornette Coleman’s storied Harmolodic studio in Harlem into a Grammy-winning recording facility. Stadiumred helped launch the careers of artists like The Chainsmokers, ultimately leading to the company being associated with 30 Grammy nominations and 22 wins, including with the likes of Eminem, Drake, and many more.

As CEO of Stadiumred Group, Zdanow transformed the company from a Grammy-winning recording studio into a unified marketing collective offering creative, digital, experiential, and influencer services. He led the strategic integration of multiple agencies, building a platform that served global brands and attracted top clients including 7-Eleven, Brown-Forman, Disney’s FX Networks, Steven Soderbergh’s Singani 63, Peter Thomas Roth, Pernod Ricard, and Rolls-Royce. Under his leadership, Stadiumred was recognized as one of Adweek’s Fastest Growing Agencies and earned a spot on the Inc. 5000 list.

Leading ONAR Holdings and Supporting the Middle Market

After exiting his prior advertising firm in 2021, Zdanow was recruited to lead ONAR Holdings (OTCQB: ONAR), a marketing technology company and agency network. ONAR focuses on delivering AI-driven strategies that help middle-market companies grow revenue, often companies too small to attract Fortune 500-level attention, but large enough to need advanced solutions. ONAR specializes in companies generating revenue in the range of $50 million to $1 billion. 

“We help people sell stuff,” Zdanow told TechMediaWire. “We own and operate businesses that help middle-market companies generate revenue online.” In that vein, ONAR’s businesses include:

• Storia – Specializes in digital performance marketing and e-commerce growth.
• Of Kos – Focuses on B2B healthcare marketing and revenue acceleration.
• ONAR Labs – A tech incubator driving innovation in ad tech and AI.

Together, these units serve clients across America, with a global team projected to expand through 2025.

Strategic Acquisitions and AI at the Core

Zdanow outlined ONAR’s aggressive acquisition strategy, with several deals expected by the end of 2025. In February, ONAR announced a letter of intent to acquire a marketing technology firm that will merge into Storia, doubling that unit’s revenue and boosting EBITDA through scale and automation.

Artificial intelligence is central to ONAR’s operations. “There are some interesting things we do with tech and AI to really enable what we’re offering,” said Zdanow. ONAR’s AI systems have cut creative production time substantially and improved campaign performance, giving middle-market clients enterprise-grade results.

Vision for the Future

Zdanow’s goal is to build a category-defining holding company focused on marketing outcomes rather than just branding. “We’re not chasing the Fortune 100s,” he said. “There’s real opportunity among innovative mid-sized businesses, and our solutions tie directly to revenue.”

ONAR plans to uplist to Nasdaq and expand both geographically and technologically. As Zdanow told TechMediaWire, ONAR is doing it “better, faster, and smarter”—and the market is noticing.

For more information, visit the company’s website at www.ONAR.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR are available in the company’s newsroom at https://ibn.fm/ONAR

• The company has filed to open an account with Coinbase Prime to manage custody and transactions securely.
• This move follows similar strategies from MicroStrategy and SharpLink Gaming, blending clean energy with digital asset exposure.
• Bitcoin holdings are intended to hedge against inflation and diversify SolarBank’s treasury operations.
• The company maintains a core focus on solar and battery energy storage.
• Management has not yet purchased Bitcoin; allocations will depend on market conditions and corporate liquidity needs.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., announced that it was integrating Bitcoin into its treasury strategy, a move that reflects a growing trend among public companies diversifying cash reserves with digital assets as a hedge against inflation and currency volatility (https://ibn.fm/h5oMU).

The company announced that it has applied to open an account with Coinbase Prime (NASDAQ: COIN), a digital asset platform offering secure custody and self-custodial wallet services. While no purchases have been made yet, the allocation is part of a broader effort to enhance financial resilience and appeal to a new category of investors. SolarBank’s decision to integrate Bitcoin as a strategic reserve asset was inspired by MicroStrategy’s multibillion-dollar Bitcoin strategy and SharpLink Gaming’s Ethereum-driven strategy, the company said.

SolarBank CEO and President Dr. Richard Lu said the decision stems from a belief in Bitcoin’s growing adoption and utility in treasury management. “As the adoption of Bitcoin continues to grow, SolarBank believes that establishing a Bitcoin treasury strategy taps into a growing sector that is seeing increasing adoption,” Lu said. “In a world of ever-increasing energy demand and treasury complexity, SolarBank delivers renewable energy solutions and recurring revenues, now combined with all of the benefits of holding Bitcoin.”

The actual timing and value of any Bitcoin purchases will be at management’s discretion, subject to liquidity, market conditions, and the price of Bitcoin. The company retains the option to pause or amend its strategy as needed.

The company cited multiple strategic motivations for the decision, such as hedging against inflation, enhancing liquidity options, and accessing institutional financing tied to digital assets. In addition, SolarBank believes the Bitcoin strategy will help distinguish it from peers in the clean energy sector, while appealing to investors focused on blockchain, decentralized finance (“DeFi”), and Web3-related themes.

SolarBank also emphasized the environmental aspect of its decision. According to the company, its clean energy generation assets, primarily solar farms and battery energy storage systems (“BESS”), help offset the emissions tied to the energy-intensive process of Bitcoin mining. While SolarBank itself is not directly involved in mining, the company presents its strategy as a responsible integration of renewable energy and digital finance.

The Bitcoin move comes at a time when the company is scaling rapidly across Canada and the United States. SolarBank recently announced several major deals, including a US$100 million U.S. community solar financing agreement with CIM Group and a US$49.5 million partnership with Qcells for Made-in-USA solar installations. It is also in the final stages of completing a US$41 million project with Honeywell to repurpose closed landfills into community solar farms.

The firm also secured a $25 million credit facility from the Royal Bank of Canada (“RBC”), which will be used to accelerate the development of BESS projects. These installations aim to stabilize the electricity grid and generate recurring revenue through long-term agreements with municipalities and utilities.

Even with the Bitcoin integration, SolarBank stated that renewable energy remains its core business. The company is targeting over 1 GW in its development pipeline and continues to partner with Tier-1 manufacturers and Fortune 500 clients in the infrastructure and utility sectors.

For more information, visit the company’s website at SolarBankCorp.com.

There are several risks associated with the development of the projects detailed in this report. The development of any project is subject to the continued availability of third-party financing arrangements for the project owners and the risks associated with the construction of a solar power project. There is no certainty the projects disclosed in this report will be completed on schedule or that they will operate in accordance with their design capacity.

This report contains forward looking information. Please refer to the press release entitled “SolarBank Announces Bitcoin Treasury Strategy” for additional details on the statements, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

MiningNews Select Australia 2025 returns this July for a transformative investor-focused event at the prestigious Crown Perth. With more than 30 junior mining companies and over 400 investor meetings scheduled, this is going to be one of the most influential mining investment events in the calendar year.

Powered by Aspermont and hosted by MiningNews.net, this event will feature selected, high-potential resources companies, many of which are working in the growing critical minerals and gold sectors. To identify the world’s leading development assets, these projects have been carefully assessed using a robust 13-metric index.

Expert Panels and Sector Intelligence

The much-awaited MiningNews Select Australia 2025 features expert-led panel discussions addressing key trends and issues facing the mining sector. These sessions provide valuable insights into topics such as capital access, project development risks, exploration strategies, and the role of critical minerals in future energy transitions.

The panel discussions aim to equip investors with key strategies that can guide portfolio decisions in the quarters ahead. This two-day event will provide investors with access to development-stage projects that show strong fundamentals but are flying under the radar. By focusing on curated, data-backed selection, investors will get an opportunity to discover hidden gems before they hit the mainstream.

Strong Institutional and Retail Interest

The event’s format ensures business executives and investors can engage in meaningful discussions about capital requirements, project timelines, and investment opportunities. Focused on results, MiningNews Select Australia 2025 features branded booths with screens and seating, a dedicated meetings concierge, and ample networking opportunities over 15+ hours throughout the two days.

Among the 30+ junior and mid-tier companies showcasing their projects at the event are:

• Alma Metals
• Antares Metals
• Asian Battery Metals
• Astral Resources
• Aurum Resources
• Australian Gold and Copper
• Copper Search
• Corazon Mining
• Cyclone Metals
• Empire Metals
• Fenix Resources
• Firetail Resources
• Horizon Minerals
• Impact Minerals
• Kalgoorlie Gold Mining
• Mt Malcolm Mines
• Olympio Metals Limited
• Pac Gold
• PolarX Limited
• Rox Resources

Each company brings a unique value proposition, from ESG alignment and resource diversification to exploration upside and expansion-ready production pipelines.

To learn more, please visit https://ibn.fm/gvqii.

• $36.93M LOI signed to acquire Hilton Garden Inn in Rancho Mirage, California, next to Disney’s Cotino development
• Follows $41M deal for Victorville Holiday Inn, set to become a model for robotics-enabled hotel operations
• Recently acquired Future Hospitality Ventures (which holds an exclusive U.S. partnership with Bear Robotics) and the addition of Skytech Automated Solutions – both aimed at expanding its AI-powered robotics initiatives in the hospitality industry
• The combined value of these acquisitions is expected to strengthen the positioning of the company for a successful uplisting, unlocking the full range of benefits associated with national exchange

As automation reshapes hospitality, hotel operators are under pressure to find cost-effective, scalable solutions that combat labor shortages, streamline operations, and elevate guest experiences. Nightfood Holdings (OTCQB: NGTF) is embracing this shift head-on with an ambitious plan to lead the industry through artificial intelligence (“AI”)-powered hotel automation and strategic acquisitions.

Strategic Moves in Key California Markets

On May 12, 2025, Nightfood announced a $36.93 million LOI to acquire the Hilton Garden Inn in Rancho Mirage, California, a 120-room hotel adjacent to Disney’s forthcoming Cotino residential resort community. The agreement includes a room expansion plan, aiming to increase capacity to 125 rooms, and a $3 million earnout payable upon completion of the expansion. Situated in a high-traffic tourist corridor, the Rancho Mirage hotel is set to become a site for showcasing Nightfood’s RaaS technology – including its currently deployed Skytech Laundry helper – and will serve as a future model for retrofitting other full-service hotels.

This move follows Nightfood’s April announcement of a $41 million acquisition of a Holiday Inn in Victorville, California. That 155-room property, now undergoing brand conversion to a Courtyard by Marriott, already is in use of the Skytech-driven laundry robotic solution. Once renovations are complete, the Victorville location will become Nightfood’s first RaaS model hotel, demonstrating how automation can improve profitability, reduce staffing burdens, and optimize service delivery.

AI-Powered RaaS Platform Driving Hospitality Innovation

Nightfood’s AI-enabled robotics are built to automate labor-intensive hotel functions, including simple housekeeping, starting with laundry transportation. By embedding these capabilities into the hotel infrastructure, the company is positioned to reduce operating costs, fill labor gaps, and create more reliable, standardized guest experiences. With staff shortages still plaguing the hospitality sector post-pandemic, Nightfood’s solution is both timely and scalable.

These advances align with the company’s broader shift into the Robotics-as-a-Service (“RaaS”) space, which combines real estate value with subscription-style recurring revenue models. This unique integration offers hotels a clear ROI path while providing Nightfood with high-margin, software-like growth dynamics.

In fact, the Victorville hotel is projected to generate 25–40% more revenue once renovations and robotic integrations are complete, validating the potential of Nightfood’s platform to transform hotel economics. Both properties will also help Nightfood test and refine robotic workflows in real-world environments before scaling to additional acquisitions.

Financial Structure and Uplisting Requirement

Nightfood will fund both deals through Series C Convertible Preferred Stock, offering sellers equity upside while preserving cash. The Rancho Mirage deal includes $26.43 million in preferred stock and a $3 million earnout, while the Victorville transaction involves a net purchase price of $31 million after factoring in the assumed mortgage, plus a $5 million performance-based earnout.

A Vision Beyond Hospitality

These strategic moves also position Nightfood within a larger trend: digitizing traditional service sectors. Much like how Amazon Go reinvented retail and Toast transformed restaurant POS, Nightfood is applying a similar logic to the hospitality industry by blending hardware, software, and data to deliver smarter, leaner operations.

As NGTF’s recent acquisitions strengthen the positioning of the company for a successful uplisting, it may emerge as a new kind of hospitality operator, part landlord, part tech innovator, and part robotics integrator.

With two high-profile hotel deals already signed, as well as its recently acquired Future Hospitality Ventures (which holds an exclusive U.S. partnership with Bear Robotics) and the acquisition of Skytech Automated Solutions, Nightfood is becoming a platform company at the intersection of real estate, robotics, and AI. Investors will be watching closely to see how this transition plays out.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF